Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Indian J Ophthalmol ; 69(10): 2824-2827, 2021 10.
Article in English | MEDLINE | ID: covidwho-1441261

ABSTRACT

Purpose: To compare the post-cataract endophthalmitis (PCE) rates among eyes undergoing syringing or regurgitation on pressure over the lacrimal sac (ROPLAS) test prior to cataract surgery. Methods: We performed a single-center, retrospective, comparative analysis of eyes developing PCE who underwent syringing prior to cataract surgery (group A) in the pre-COVID-19 era between November 1 2019 and January 31, 2020 and the eyes that underwent ROPLAS test prior to cataract surgery (group B) in the COVID-19 era between November 1, 2020 and January 31, 2021. Results: A total of 87,144 eyes underwent cataract surgery during the two time periods of the study. Syringing was performed in 48,071 eyes, whereas ROPLAS was performed in 39,073 eyes. In group A, 19 eyes (0.039%) developed PCE, whereas 20 eyes (0.051%) developed PCE in group B (P = 0.517). Between the two groups, the grade of anterior chamber cellular reaction (P = 0.675), hypopyon (P = 0.738), and vitreous haze (P = 0.664) were comparable. Gram-positive organisms were detected in 4 eyes in group A and 6 eyes in group B; 2 eyes in group A had gram-negative bacilli. The presenting visual acuity (Group A: LogMAR 1.42 and Group B: LogMAR 1.30) and final visual acuity (Group A: LogMAR 0.52 and Group B: LogMAR 0.5) were comparable between the two groups. (P = 0.544 and 0.384, respectively). Conclusion: The rates of PCE were comparable among the eyes undergoing either syringing test or ROPLAS prior to cataract surgery.


Subject(s)
COVID-19 , Cataract Extraction , Cataract , Endophthalmitis , Lacrimal Duct Obstruction , Nasolacrimal Duct , Endophthalmitis/diagnosis , Endophthalmitis/epidemiology , Endophthalmitis/etiology , Humans , Lacrimal Duct Obstruction/diagnosis , Lacrimal Duct Obstruction/epidemiology , Lacrimal Duct Obstruction/etiology , Pandemics , Retrospective Studies , SARS-CoV-2
2.
Acta Ophthalmol ; 98(8): 859-863, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-260153

ABSTRACT

BACKGROUND: The current outbreak of COVID-19 has spread rapidly all over the world. Respiratory droplets and contaction with infected patients are the two major transmission routes. However, the value of tear virus nucleic acid is still not clear. We dynamic detected the SARS-CoV-2 in eye sample of one COVID-19 patient with obstruction of common lacrimal ducts. METHODS: Besides the routine examination, nasopharyngeal and eye swab were continuously measured by polymerase chain reaction assay and next-generation sequencing (NGS). Gene detection was performed for drug use guidance, and flow cytometry was performed to analyse the lymphocyte subsets. RESULTS: Nasopharyngeal swabs were positive for 22 days, but eye swabs were still continuously positive for 2 weeks after nasopharyngeal swabs turned negative. The low level of lymphocyte and the high level IL-6 lasted for almost 4 weeks, then became near normal. Next-generation sequencing (NGS) confirmed the existing of SARS-CoV-2, HSV1 and HHV6B virus nucleic acid. The gene detection for drug use guidance showed the genetic locus ABCB1 (3435T>C) rs1045642 belonged to type CC and it mean the efficiency of lopinavir-ritonavir would be significantly decreased. The flow cytometry of lymphocyte subsets showed PD-1+  CD95+ cells was accounting for 94.8% in CD3+  CD8+ T subset and for 94.8% in CD3+  TCRγδ+ T subset. CONCLUSIONS: As obstruction of common lacrimal duct, positively detection in one eye for 2 weeks more after nasopharyngeal swab became negative. More eye swabs should be collected from COVID-19 patients, especially from those immunocompromised, those with eye symptoms and those had a history of ocular diseases.


Subject(s)
COVID-19/diagnosis , Conjunctiva/virology , Eye Infections, Viral/diagnosis , Herpesvirus 1, Human/isolation & purification , Herpesvirus 6, Human/isolation & purification , Lacrimal Duct Obstruction/diagnosis , SARS-CoV-2/isolation & purification , Tears/virology , Aged , Anti-Bacterial Agents/therapeutic use , COVID-19/drug therapy , COVID-19/virology , Conjunctivitis, Viral/diagnosis , Drug Therapy, Combination , Eye Infections, Viral/drug therapy , Eye Infections, Viral/virology , Flow Cytometry , HIV Protease Inhibitors/therapeutic use , Herpes Simplex/diagnosis , Herpes Simplex/drug therapy , Herpes Simplex/virology , Herpesvirus 1, Human/genetics , Herpesvirus 6, Human/genetics , High-Throughput Nucleotide Sequencing , Humans , Lacrimal Duct Obstruction/drug therapy , Lacrimal Duct Obstruction/virology , Lopinavir/therapeutic use , Male , Medicine, Chinese Traditional , Moxifloxacin/therapeutic use , Nasopharynx/virology , Nucleic Acids/genetics , Polymerase Chain Reaction , RNA, Viral/genetics , Ritonavir/therapeutic use , Roseolovirus Infections/diagnosis , Roseolovirus Infections/drug therapy , Roseolovirus Infections/virology , SARS-CoV-2/genetics
SELECTION OF CITATIONS
SEARCH DETAIL